Avidity Biosciences, Inc.【RNAM】Cash flow
Market cap
$2.1B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 4 | 17 | 27 | 38 | 51 |
| Cash from operations | -37 | -95 | -136 | -119 | -301 |
| Capital expenditures | -1 | -4 | -3 | -4 | -7 |
| Cash from investing | -8 | -83 | -190 | -130 | -854 |
| Repayments of term debt | 5 | - | - | - | - |
| Cash from financing | 272 | 176 | 346 | 94 | 1,192 |
| Free cash flow | |||||
| FCF margin (%) |